HPLC chromatogram
Reverse-phase trace
Single peak at the expected retention time. Area % integration shown on every lot record. Per-lot chromatogram available on request from our supplier, Janoshik.
Metabolic Pathways
Retatrutide
Triple-agonist peptide of GLP-1, GIP, and glucagon receptors. Phase 2 trial published in NEJM 2023.[1]
Variants
Quantity
1
PayPal or cash on collection · UK 18+ verification at dispatch · For laboratory research use only
Reconstitution
Math, not dosing
For 10mg vial + 2 mL BAC water → concentration calculation on the dedicated calculator page. We provide research procedure only.
Selected research · Retatrutide
- [1]Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Phase 2 randomised trial of retatrutide in 338 adults with obesity. 24% body-weight reduction at 48 weeks.PMID 37366315 →
All references describe published research on the compound. They do not constitute clinical guidance or imply therapeutic benefit to any individual purchaser. For laboratory research use only.
Frequently bought together
All compounds →AOD 9604
Modified fragment of human growth hormone (hGH 176-191). Studied in preclinical research examining lipid-metabolism pathways.
From £35.00
L-Carnitine
Amino acid derivative involved in fatty-acid transport into mitochondria. Frequently referenced in metabolic research alongside GLP-1-class compounds.
From £32.00